Clopidogrel should not be administered to patients with hematopoeitic disorders such as neutropenia or thrombocytopenia, haemorrhagic diathesis or other hemorrhagic disorders associated with a prolonged bleeding time, or conditions with an increased risk of bleeding such as gastrointestinal ulcers, acute cerebral hemorrhage or severe liver dysfunction. Full blood counts should be performed before starting treatment and every 2 weeks during the first 3 months of therapy.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
